Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 2020 - 14
Main Authors Hu, Xiaomeng, Manner, Karl, DeJesus, Rowena, White, Kathy, Gattis, Corie, Ngo, Priscilla, Bandoro, Christopher, Tham, Eleonore, Chu, Elaine Y., Young, Chi, Wells, Frank, Basco, Ronald, Friera, Annabelle, Kangeyan, Divy, Beauchesne, Pascal, Dowdle, William E., Deuse, Tobias, Fry, Terry J., Foster, Aaron E., Schrepfer, Sonja
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 10.04.2023
Nature Publishing Group
Nature Portfolio
Subjects
13/106
13/109
13/31
14/5
38
38/5
59
59/5
631/250/2152/2153
64
64/60
692/4028/67
Animals
Antigens
Cancer
CD19 antigen
CD47 Antigen
Chimeric antigen receptors
CIITA protein
CRISPR
Effectiveness
Hematopoietic Stem Cell Transplantation
Humanities and Social Sciences
Humans
Immune clearance
Immune system
Immunocompetence
Immunodeficiency
Immunotherapy
Lymphocytes
Lymphocytes T
Manufacturing
Mice
multidisciplinary
Neoplasms
Receptors
Receptors, Antigen, T-Cell - genetics
Receptors, Chimeric Antigen - genetics
Rejection
Science
Science (multidisciplinary)
T-Lymphocytes
Tumors
Online AccessGet full text

Cover

Abstract Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA , and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19 + tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses. The development of allogeneic chimaeric antigen receptor (CAR) T cells could overcome manufacturing bottlenecks for immunotherapy. However, immune rejection reduces the persistence and efficacy of these cells. Here, the authors generate allogeneic anti-CD19 CAR T cells that can evade the immune system and provide durable anti-tumour responses.
AbstractList Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA, and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19+ tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses.The development of allogeneic chimaeric antigen receptor (CAR) T cells could overcome manufacturing bottlenecks for immunotherapy. However, immune rejection reduces the persistence and efficacy of these cells. Here, the authors generate allogeneic anti-CD19 CAR T cells that can evade the immune system and provide durable anti-tumour responses.
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA, and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19 tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses.
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA, and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19+ tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses.Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA, and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19+ tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses.
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA , and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19 + tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses. The development of allogeneic chimaeric antigen receptor (CAR) T cells could overcome manufacturing bottlenecks for immunotherapy. However, immune rejection reduces the persistence and efficacy of these cells. Here, the authors generate allogeneic anti-CD19 CAR T cells that can evade the immune system and provide durable anti-tumour responses.
Abstract Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA, and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19+ tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses.
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA , and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19 + tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses.
ArticleNumber 2020
Author Manner, Karl
Tham, Eleonore
DeJesus, Rowena
Chu, Elaine Y.
Wells, Frank
Ngo, Priscilla
Basco, Ronald
Friera, Annabelle
Dowdle, William E.
Foster, Aaron E.
Hu, Xiaomeng
Deuse, Tobias
White, Kathy
Kangeyan, Divy
Fry, Terry J.
Gattis, Corie
Young, Chi
Bandoro, Christopher
Beauchesne, Pascal
Schrepfer, Sonja
Author_xml – sequence: 1
  givenname: Xiaomeng
  surname: Hu
  fullname: Hu, Xiaomeng
  organization: Sana Biotechnology Inc
– sequence: 2
  givenname: Karl
  surname: Manner
  fullname: Manner, Karl
  organization: Sana Biotechnology Inc
– sequence: 3
  givenname: Rowena
  surname: DeJesus
  fullname: DeJesus, Rowena
  organization: Sana Biotechnology Inc
– sequence: 4
  givenname: Kathy
  surname: White
  fullname: White, Kathy
  organization: Sana Biotechnology Inc
– sequence: 5
  givenname: Corie
  surname: Gattis
  fullname: Gattis, Corie
  organization: Sana Biotechnology Inc
– sequence: 6
  givenname: Priscilla
  surname: Ngo
  fullname: Ngo, Priscilla
  organization: Sana Biotechnology Inc
– sequence: 7
  givenname: Christopher
  surname: Bandoro
  fullname: Bandoro, Christopher
  organization: Sana Biotechnology Inc
– sequence: 8
  givenname: Eleonore
  surname: Tham
  fullname: Tham, Eleonore
  organization: Sana Biotechnology Inc
– sequence: 9
  givenname: Elaine Y.
  orcidid: 0000-0001-9493-5859
  surname: Chu
  fullname: Chu, Elaine Y.
  organization: Sana Biotechnology Inc
– sequence: 10
  givenname: Chi
  orcidid: 0000-0003-2424-0060
  surname: Young
  fullname: Young, Chi
  organization: Sana Biotechnology Inc
– sequence: 11
  givenname: Frank
  surname: Wells
  fullname: Wells, Frank
  organization: Sana Biotechnology Inc
– sequence: 12
  givenname: Ronald
  surname: Basco
  fullname: Basco, Ronald
  organization: Sana Biotechnology Inc
– sequence: 13
  givenname: Annabelle
  surname: Friera
  fullname: Friera, Annabelle
  organization: Sana Biotechnology Inc
– sequence: 14
  givenname: Divy
  surname: Kangeyan
  fullname: Kangeyan, Divy
  organization: Sana Biotechnology Inc
– sequence: 15
  givenname: Pascal
  surname: Beauchesne
  fullname: Beauchesne, Pascal
  organization: Sana Biotechnology Inc
– sequence: 16
  givenname: William E.
  surname: Dowdle
  fullname: Dowdle, William E.
  organization: Sana Biotechnology Inc
– sequence: 17
  givenname: Tobias
  orcidid: 0000-0002-9695-4006
  surname: Deuse
  fullname: Deuse, Tobias
  organization: Department of Surgery, Division of Cardiothoracic Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California San Francisco
– sequence: 18
  givenname: Terry J.
  surname: Fry
  fullname: Fry, Terry J.
  organization: Sana Biotechnology Inc
– sequence: 19
  givenname: Aaron E.
  surname: Foster
  fullname: Foster, Aaron E.
  organization: Sana Biotechnology Inc
– sequence: 20
  givenname: Sonja
  orcidid: 0000-0002-7696-6229
  surname: Schrepfer
  fullname: Schrepfer, Sonja
  email: Sonja.Schrepfer@sana.com
  organization: Sana Biotechnology Inc
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37037829$$D View this record in MEDLINE/PubMed
BookMark eNp9ks9uEzEQxleoiJbSF-CALHHhsrD-k9g-IRRaWqkSl3K2vPYkceS1F9tbKX0BXhsnaaHtob7Ymvm-n8Yz87Y5CjFA07zH3WfcUfElM8zmvO0IbSnnYtaSV80J6RhuMSf06NH7uDnLedPVQyUWjL1pjinvKBdEnjR_LrdjdMMwBUA6FNcuvmOJzNoNkJzZh1YQUAIDY4kJ3SAD3mc0pnjrLCCvc3Fhhco01KyJoaTokQtoOXm_RXtyNHEYoUAoSHsfKw8qej0NOrg7sGhwBt41r5faZzi7v0-bXxfnN4vL9vrnj6vFt-vWzBguLVitKbBOWiOXsptZzawAqonGsqcEuOxnxjBheG-EFkIA7ikToKXltreGnjZXB66NeqPG5Aadtipqp_aBmFZKp-KMB4Wx5kwKK_o5YYYvJZFUW-BESwZzSyvr64E1Tv0A1tQPJu2fQJ9mglurVbxVuOvEvCO8Ej7dE1L8PUEuanB512AdIE5ZES6lIHMiWJV-fCbdxCmF2qudSghOGd-pPjwu6V8tDwOvAnEQmBRzTrBUxhVd3G5w2vlamtqtlzqsl6rrpfbrpUi1kmfWB_qLJnow5SoOK0j_y37B9RfnheWY
CitedBy_id crossref_primary_10_3390_cells13020146
crossref_primary_10_3390_cells13171480
crossref_primary_10_1016_j_blre_2024_101241
crossref_primary_10_1128_spectrum_00436_24
crossref_primary_10_1016_j_xphs_2023_08_001
crossref_primary_10_1016_j_ymthe_2024_06_022
crossref_primary_10_1136_jitc_2024_009198
crossref_primary_10_1016_j_apsb_2024_04_022
crossref_primary_10_3389_fimmu_2024_1354825
crossref_primary_10_1186_s13287_024_03810_4
crossref_primary_10_1111_ejh_14039
crossref_primary_10_1038_s44222_024_00219_9
crossref_primary_10_1111_imr_13254
crossref_primary_10_1038_s41586_024_07443_8
crossref_primary_10_1186_s12943_024_01938_8
crossref_primary_10_46989_001c_121404
crossref_primary_10_1016_j_omton_2024_200885
crossref_primary_10_1038_s41587_024_02531_6
crossref_primary_10_1186_s13046_025_03273_2
crossref_primary_10_1146_annurev_cancerbio_062822_023316
crossref_primary_10_1186_s11658_024_00561_1
crossref_primary_10_3389_fmolb_2024_1447315
crossref_primary_10_3390_ijms241310873
crossref_primary_10_1016_j_stem_2024_02_001
crossref_primary_10_1182_bloodadvances_2022009397
crossref_primary_10_3389_fimmu_2024_1531294
crossref_primary_10_1016_j_bioactmat_2024_08_046
crossref_primary_10_4049_jimmunol_2400491
crossref_primary_10_1016_j_ijpharm_2024_124779
crossref_primary_10_1038_s41577_024_01022_8
crossref_primary_10_1002_cti2_70022
crossref_primary_10_1182_bloodadvances_2024013436
crossref_primary_10_1038_s41568_024_00723_5
crossref_primary_10_3389_fimmu_2025_1512494
crossref_primary_10_3390_cells13221892
crossref_primary_10_1101_cshperspect_a041371
crossref_primary_10_1158_2326_6066_CIR_23_0679
crossref_primary_10_1016_j_omtm_2024_101255
crossref_primary_10_1016_j_tips_2025_02_009
crossref_primary_10_1016_j_stem_2023_10_003
Cites_doi 10.1182/blood.V88.8.3230.bloodjournal8883230
10.1038/s41587-019-0016-3
10.1200/CCI.19.00086
10.1073/pnas.2022091118
10.1158/2326-6066.CIR-18-0508
10.1038/s41571-021-00485-1
10.1038/nbt.3525
10.1089/hum.2017.254
10.1182/blood-2012-01-405365
10.1038/s41577-021-00547-6
10.1038/s41573-019-0051-2
10.1056/NEJMra1706169
10.1016/S2352-3026(20)30277-5
10.1038/s43018-021-00244-2
10.1182/blood.2021010784
10.1038/319675a0
10.1016/j.jcyt.2017.06.009
10.1016/S0140-6736(20)32334-5
10.1084/jem.20200839
10.1182/blood-2011-02-337360
10.21037/cco.2018.04.02
10.1038/s41467-019-11869-4
10.3390/cells7100155
10.1038/s41571-021-00476-2
10.1038/s43018-022-00383-0
10.1111/bjh.18506
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
SOI
7X8
5PM
DOA
DOI 10.1038/s41467-023-37785-2
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Collection (ProQuest)
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database (ProQuest)
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE
MEDLINE - Academic


CrossRef
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 14
ExternalDocumentID oai_doaj_org_article_11a7498d8b624c7f9293ade72a94e6d3
PMC10086027
37037829
10_1038_s41467_023_37785_2
Genre Journal Article
GrantInformation_xml – fundername: NIH HHS
  grantid: S10 OD027023
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LK8
M1P
M48
M7P
M~E
NAO
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AARCD
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
SOI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c541t-edaa3e409dc9f905da4d8e3a2a19b32e79b5cc48c7bc8a888e1b348ea9d7dbdc3
IEDL.DBID M48
ISSN 2041-1723
IngestDate Wed Aug 27 01:24:07 EDT 2025
Thu Aug 21 18:38:25 EDT 2025
Tue Aug 05 09:51:18 EDT 2025
Wed Aug 13 04:43:23 EDT 2025
Mon Jul 21 06:00:40 EDT 2025
Thu Apr 24 22:58:56 EDT 2025
Tue Jul 01 00:58:47 EDT 2025
Fri Feb 21 02:39:59 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-edaa3e409dc9f905da4d8e3a2a19b32e79b5cc48c7bc8a888e1b348ea9d7dbdc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2424-0060
0000-0002-9695-4006
0000-0001-9493-5859
0000-0002-7696-6229
OpenAccessLink https://www.proquest.com/docview/2798873474?pq-origsite=%requestingapplication%
PMID 37037829
PQID 2798873474
PQPubID 546298
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_11a7498d8b624c7f9293ade72a94e6d3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10086027
proquest_miscellaneous_2799826284
proquest_journals_2798873474
pubmed_primary_37037829
crossref_citationtrail_10_1038_s41467_023_37785_2
crossref_primary_10_1038_s41467_023_37785_2
springer_journals_10_1038_s41467_023_37785_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-04-10
PublicationDateYYYYMMDD 2023-04-10
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-10
  day: 10
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationTitleAlternate Nat Commun
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Depil, Duchateau, Grupp, Mufti, Poirot (CR9) 2020; 19
CR17
CR16
Graham, Jozwik, Pepper, Benjamin (CR6) 2018; 7
De Lima Lopes, Nahas (CR3) 2018; 7
Deuse (CR13) 2021; 218
Hirabayashi (CR18) 2021; 2
Benjamin (CR10) 2020; 396
Wang (CR15) 2011; 118
Lipsitz, Timmins, Zandstra (CR5) 2016; 34
Torikai (CR8) 2012; 119
Foster (CR25) 2021; 137
Anagnostou, Riaz, Hashmi, Murad, Kenderian (CR2) 2020; 7
Kagoya (CR11) 2020; 8
Cooke (CR27) 1996; 88
Deuse (CR14) 2019; 37
Ullman-Cullere, Foltz (CR26) 1999; 49
DiNofia, Grupp (CR4) 2021; 18
Lipsitz (CR21) 2017; 19
Jin (CR19) 2019; 10
Morris, Neelapu, Giavridis, Sadelain (CR24) 2022; 22
Wagner (CR23) 2021; 18
Tully (CR20) 2019; 3
June, Sadelain (CR1) 2018; 379
Karre, Ljunggren, Piontek, Kiessling (CR12) 1986; 319
Kohl, Arsenieva, Holzinger, Abken (CR7) 2018; 29
Deuse (CR22) 2021; 118
AM DiNofia (37785_CR4) 2021; 18
CH June (37785_CR1) 2018; 379
U Kohl (37785_CR7) 2018; 29
R Benjamin (37785_CR10) 2020; 396
YY Lipsitz (37785_CR5) 2016; 34
MH Ullman-Cullere (37785_CR26) 1999; 49
X Wang (37785_CR15) 2011; 118
S Depil (37785_CR9) 2020; 19
L Jin (37785_CR19) 2019; 10
T Deuse (37785_CR13) 2021; 218
K Karre (37785_CR12) 1986; 319
K Hirabayashi (37785_CR18) 2021; 2
EC Morris (37785_CR24) 2022; 22
T Deuse (37785_CR14) 2019; 37
T Deuse (37785_CR22) 2021; 118
Y Kagoya (37785_CR11) 2020; 8
G De Lima Lopes (37785_CR3) 2018; 7
KR Cooke (37785_CR27) 1996; 88
S Tully (37785_CR20) 2019; 3
DL Wagner (37785_CR23) 2021; 18
C Graham (37785_CR6) 2018; 7
T Anagnostou (37785_CR2) 2020; 7
YY Lipsitz (37785_CR21) 2017; 19
H Torikai (37785_CR8) 2012; 119
37785_CR17
MC Foster (37785_CR25) 2021; 137
37785_CR16
References_xml – volume: 88
  start-page: 3230
  year: 1996
  end-page: 3239
  ident: CR27
  article-title: An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin
  publication-title: Blood
  doi: 10.1182/blood.V88.8.3230.bloodjournal8883230
– volume: 37
  start-page: 252
  year: 2019
  end-page: 258
  ident: CR14
  article-title: Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-019-0016-3
– ident: CR16
– volume: 3
  start-page: 1
  year: 2019
  end-page: 9
  ident: CR20
  article-title: Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model
  publication-title: JCO Clin. Cancer Inform.
  doi: 10.1200/CCI.19.00086
– volume: 49
  start-page: 319
  year: 1999
  end-page: 323
  ident: CR26
  article-title: Body condition scoring: a rapid and accurate method for assessing health status in mice
  publication-title: Lab. Anim. Sci.
– volume: 118
  start-page: e2022091118
  year: 2021
  ident: CR22
  article-title: Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2022091118
– volume: 8
  start-page: 926
  year: 2020
  end-page: 936
  ident: CR11
  article-title: Genetic Ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0508
– volume: 18
  start-page: 195
  year: 2021
  end-page: 196
  ident: CR4
  article-title: Will allogeneic CAR T cells for CD19(+) malignancies take autologous CAR T cells ‘off the shelf’?
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-021-00485-1
– volume: 34
  start-page: 393
  year: 2016
  end-page: 400
  ident: CR5
  article-title: Quality cell therapy manufacturing by design
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3525
– volume: 29
  start-page: 559
  year: 2018
  end-page: 568
  ident: CR7
  article-title: CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications
  publication-title: Hum. Gene Ther.
  doi: 10.1089/hum.2017.254
– volume: 119
  start-page: 5697
  year: 2012
  end-page: 5705
  ident: CR8
  article-title: A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
  publication-title: Blood
  doi: 10.1182/blood-2012-01-405365
– volume: 22
  start-page: 85
  year: 2022
  end-page: 96
  ident: CR24
  article-title: Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-021-00547-6
– volume: 19
  start-page: 185
  year: 2020
  end-page: 199
  ident: CR9
  article-title: ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-019-0051-2
– volume: 379
  start-page: 64
  year: 2018
  end-page: 73
  ident: CR1
  article-title: Chimeric antigen receptor therapy
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra1706169
– volume: 7
  start-page: e816
  year: 2020
  end-page: e826
  ident: CR2
  article-title: Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis
  publication-title: Lancet Haematol.
  doi: 10.1016/S2352-3026(20)30277-5
– volume: 2
  start-page: 904
  year: 2021
  end-page: 918
  ident: CR18
  article-title: Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00244-2
– volume: 137
  start-page: 3306
  year: 2021
  end-page: 3309
  ident: CR25
  article-title: Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity
  publication-title: Blood
  doi: 10.1182/blood.2021010784
– volume: 319
  start-page: 675
  year: 1986
  end-page: 678
  ident: CR12
  article-title: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
  publication-title: Nature
  doi: 10.1038/319675a0
– ident: CR17
– volume: 19
  start-page: 1383
  year: 2017
  end-page: 1391
  ident: CR21
  article-title: A roadmap for cost-of-goods planning to guide economic production of cell therapy products
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2017.06.009
– volume: 396
  start-page: 1885
  year: 2020
  end-page: 1894
  ident: CR10
  article-title: Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32334-5
– volume: 218
  start-page: e20200839
  year: 2021
  ident: CR13
  article-title: The SIRPalpha-CD47 immune checkpoint in NK cells
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20200839
– volume: 118
  start-page: 1255
  year: 2011
  end-page: 1263
  ident: CR15
  article-title: A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
  publication-title: Blood
  doi: 10.1182/blood-2011-02-337360
– volume: 7
  start-page: 21
  year: 2018
  ident: CR3
  article-title: Chimeric antigen receptor T cells, a savior with a high price
  publication-title: Chin. Clin. Oncol.
  doi: 10.21037/cco.2018.04.02
– volume: 10
  year: 2019
  ident: CR19
  article-title: CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
  publication-title: Nat. Commun
  doi: 10.1038/s41467-019-11869-4
– volume: 7
  start-page: 155
  year: 2018
  ident: CR6
  article-title: Allogeneic CAR-T cells: more than ease of access?
  publication-title: Cells
  doi: 10.3390/cells7100155
– volume: 18
  start-page: 379
  year: 2021
  end-page: 393
  ident: CR23
  article-title: Immunogenicity of CAR T cells in cancer therapy
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-021-00476-2
– volume: 118
  start-page: 1255
  year: 2011
  ident: 37785_CR15
  publication-title: Blood
  doi: 10.1182/blood-2011-02-337360
– volume: 137
  start-page: 3306
  year: 2021
  ident: 37785_CR25
  publication-title: Blood
  doi: 10.1182/blood.2021010784
– volume: 19
  start-page: 1383
  year: 2017
  ident: 37785_CR21
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2017.06.009
– volume: 19
  start-page: 185
  year: 2020
  ident: 37785_CR9
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-019-0051-2
– volume: 18
  start-page: 195
  year: 2021
  ident: 37785_CR4
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-021-00485-1
– volume: 88
  start-page: 3230
  year: 1996
  ident: 37785_CR27
  publication-title: Blood
  doi: 10.1182/blood.V88.8.3230.bloodjournal8883230
– volume: 7
  start-page: e816
  year: 2020
  ident: 37785_CR2
  publication-title: Lancet Haematol.
  doi: 10.1016/S2352-3026(20)30277-5
– volume: 18
  start-page: 379
  year: 2021
  ident: 37785_CR23
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-021-00476-2
– volume: 10
  year: 2019
  ident: 37785_CR19
  publication-title: Nat. Commun
  doi: 10.1038/s41467-019-11869-4
– volume: 34
  start-page: 393
  year: 2016
  ident: 37785_CR5
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3525
– volume: 7
  start-page: 21
  year: 2018
  ident: 37785_CR3
  publication-title: Chin. Clin. Oncol.
  doi: 10.21037/cco.2018.04.02
– volume: 396
  start-page: 1885
  year: 2020
  ident: 37785_CR10
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32334-5
– volume: 3
  start-page: 1
  year: 2019
  ident: 37785_CR20
  publication-title: JCO Clin. Cancer Inform.
  doi: 10.1200/CCI.19.00086
– ident: 37785_CR17
  doi: 10.1038/s43018-022-00383-0
– volume: 8
  start-page: 926
  year: 2020
  ident: 37785_CR11
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0508
– volume: 2
  start-page: 904
  year: 2021
  ident: 37785_CR18
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00244-2
– volume: 49
  start-page: 319
  year: 1999
  ident: 37785_CR26
  publication-title: Lab. Anim. Sci.
– volume: 218
  start-page: e20200839
  year: 2021
  ident: 37785_CR13
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20200839
– volume: 319
  start-page: 675
  year: 1986
  ident: 37785_CR12
  publication-title: Nature
  doi: 10.1038/319675a0
– volume: 118
  start-page: e2022091118
  year: 2021
  ident: 37785_CR22
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2022091118
– volume: 22
  start-page: 85
  year: 2022
  ident: 37785_CR24
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-021-00547-6
– volume: 37
  start-page: 252
  year: 2019
  ident: 37785_CR14
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-019-0016-3
– volume: 29
  start-page: 559
  year: 2018
  ident: 37785_CR7
  publication-title: Hum. Gene Ther.
  doi: 10.1089/hum.2017.254
– ident: 37785_CR16
  doi: 10.1111/bjh.18506
– volume: 7
  start-page: 155
  year: 2018
  ident: 37785_CR6
  publication-title: Cells
  doi: 10.3390/cells7100155
– volume: 379
  start-page: 64
  year: 2018
  ident: 37785_CR1
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra1706169
– volume: 119
  start-page: 5697
  year: 2012
  ident: 37785_CR8
  publication-title: Blood
  doi: 10.1182/blood-2012-01-405365
SSID ssj0000391844
Score 2.5924456
Snippet Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at...
Abstract Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2020
SubjectTerms 13/106
13/109
13/31
14/5
38
38/5
59
59/5
631/250/2152/2153
64
64/60
692/4028/67
Animals
Antigens
Cancer
CD19 antigen
CD47 Antigen
Chimeric antigen receptors
CIITA protein
CRISPR
Effectiveness
Hematopoietic Stem Cell Transplantation
Humanities and Social Sciences
Humans
Immune clearance
Immune system
Immunocompetence
Immunodeficiency
Immunotherapy
Lymphocytes
Lymphocytes T
Manufacturing
Mice
multidisciplinary
Neoplasms
Receptors
Receptors, Antigen, T-Cell - genetics
Receptors, Chimeric Antigen - genetics
Rejection
Science
Science (multidisciplinary)
T-Lymphocytes
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQpUpcEKU8AgUZiRtEjR-J7SMUqhUSnFqpN8uPiRoJsqtu9rD8Af52x0522-VRLlxtx7LmPbHnG0LeCIdBddvwshUxljKgpmsjVdlEV-lQOYAmFQp_-drMzuXni_riVquv9CZshAceCXfMmFPS6Kh9w2VQLbpz4SIo7oyEJmacT_R5t5KpbIOFwdRFTlUyldDHS5ltAroo1Cml65LveKIM2P-nKPP3x5K_3JhmR3T6kDyYIkj6fjz5AbkH_SOyP_aUXB-Sn7P1Yt6lqg-gSLWuPPnIDA2XXb6ayUMoMxQNHSww36ZnNP27X9KpJI9iNJ1eQtNh9R1np5fstOtp-lG_pnnneZii7YGme3vcD3Dr3O6v-wGRphb3j8n56aezk1k5dVsoQy3ZUEJ0TgCmezGY1lR1dDJqEI47ZrzgoIyvQ5A6KB-0w8QZmBdSgzNRRR-DeEL2-nkPzwitW1f7xreRBy61dxiE1ExF2TagGDKxIGxDeRsmKPLUEeObzVfiQtuRWxa5ZTO3LC_I2-03ixGI487VHxJDtysTiHYeQNGyk2jZf4lWQY424mAnzV5angDelJBKFuT1dhp1MjHL9TBf5TUG0zb0_AV5OkrP9iQCTSxGZaYgekeudo66O9N3lxn3O-EwNRVH8r3biODNuf5Oi-f_gxYvyH2edCehXFZHZG-4WsFLDMcG_ypr3jWpEzOf
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9QwFLagCIkLYidQkJG4QdTEdmL7hKBQjZDg1Epzi7yFRirJ0Mkchj_A3-Y9x5NqWHqNPZbHb_Hb_D1CXnMDRnVbs7zl3ufCgaQrLWRee1MoV5gQanwo_OVrvTgTn5fVMgXc1qmscqcTo6L2g8MY-RFDYC3JhRTvVj9y7BqF2dXUQuMmuYXQZVjSJZdyjrEg-rkSIr2VKbg6WouoGeCiAsmSqsrZ3n0UYfv_ZWv-XTL5R940Xkcn98jdZEfS9xPh75MboX9Abk-dJbcPya_FdjV0-PYjUDi7Lj_-WGrqzruYoImfgHMoqLuwAq-bnlKM4K9pephHwabGemg6br7DaKpnp11PMVy_pXHlwSWbe6SYvYf1Aiwdm_51P4On2Oj-ETk7-XR6vMhTz4XcVaIc8-CN4QGcPu90q4vKG-FV4IaZUlvOgtS2ck4oJ61TBtznUFouVDDaS2-944_JQT_04SmhVWsqW9vWM8eEsgZMkaqUXrR1kKVwMiPl7uQblwDJsS_GRRMT41w1E7UaoFYTqdWwjLyZf7Oa4Diunf0BCTrPRCjt-GG4_NYkyQQXyEihlVe2ZrCrFuxFbnyQzGgRas8zcrhjhybJ97q54saMvJqHQTKRWKYPwybO0eC8wf2fkScT98w74aBowTbTGVF7fLW31f2RvjuP6N-IxlQXDI7v7Y4Fr_b1_7N4dv3feE7uMJQKRLEsDsnBeLkJL8DcGu3LKFO_Af2UK2o
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LixQxEA7LiuBFfNu6SgRv2tidpPM46ugyCHrahb01eVS7Ddo97PQcxj_g37aSfsjoKnjNiyJVlVQlVV8R8pJbNKobyfKGh5ALj5qujVC5DLbQvrAAMiYKf_os1-fi40V1cUTYnAuTgvYTpGU6pufosDdbkVQabxhUCaWrHI_dGxG6PUr1Sq6Wd5WIeK6FmPJjCq6vmXpwByWo_uvsyz_DJH_7K01X0OkdcnuyHenbkdq75Ai6e-TmWE1yf5_8WO83fRvzPYDifrX56n1pqL9s06dMakJpoXjEwQY9bXpG46v9lk7JeBTt6BgDTYfdN-ydYthp29H4RL-naeXeT3b2QOOPPa4HuHQq9Nd-h0BjcfsH5Pz0w9lqnU91FnJfiXLIIVjLAR294E1jiipYETRwy2xpHGegjKu8F9or57VFlxlKx4UGa4IKLnj-kBx3fQePCa0aWznpmsA8E9pZND-qUgXRSFCl8Coj5bzztZ9AyGMtjK91-gznuh65VSO36sStmmXk1TJnM0Jw_HP0u8jQZWSEz04N_dWXehIndHusEkYH7SRDqhq0EbkNoJg1AmTgGTmZxaGedHpbswjtprhQIiMvlm7Uxsgs20G_S2MMOmx452fk0Sg9CyUcD1e0x0xG9IFcHZB62NO1lwnxOyIwyYLh9r2eRfAXXX_fiyf_N_wpucWilkQky-KEHA9XO3iGJtfgnicd-wkp3Cke
  priority: 102
  providerName: Springer Nature
Title Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
URI https://link.springer.com/article/10.1038/s41467-023-37785-2
https://www.ncbi.nlm.nih.gov/pubmed/37037829
https://www.proquest.com/docview/2798873474
https://www.proquest.com/docview/2799826284
https://pubmed.ncbi.nlm.nih.gov/PMC10086027
https://doaj.org/article/11a7498d8b624c7f9293ade72a94e6d3
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfGJiReEN8ERmUk3iCQ2E5sPyDUlZWq0iYEq9S3yLEdFmlLSptKlH-Af5uzkxQVChIvjWS7lnW-j9_57DuEXlAFoLpISVhQY0KmQdKFZDxMjYqEjpS1qXsofHaeTmZsOk_mB6gvd9QRcLXXtXP1pGbLq9ffvm7egcC_bZ-Mizcr5sUdrA-ICxdJCCr5CCwTd4J61sF9r5mpBIfGBZpJxOIQbDft3tHsn2bHVvmU_vtw6J_XKX-LqXpTNb6DbncYEw9bpriLDmx1D91sq05u7qMfk82iLt27EIuBrmU4eh9LrC9LH7zxTcBVGFShXYBHji-wO91f4e7RHga87e5K42Z9Db3dXXdcVtgd5W-wn7nWHR5vsIvsw3wWpvYFAcvv1uBr0E8P0Gx8ejGahF09hlAnLG5Ca5SiFhxCo2Uho8QoZoSliqhY5pRYLvNEayY0z7VQ4FrbOKdMWCUNN7nR9CE6rOrKPkY4KVSSp3lhiCZM5ApgShJzw4rU8phpHqC4p3ymu2TlrmbGVeaD5lRk7W5lsFuZ362MBOjl9j-LNlXHP0efuA3djnRptn1DvfySdVIL7pHiTAoj8pTAqgrAklQZy4mSzKaGBui4Z4esZ92MuBRwnDLOAvR82w1S6zZLVbZe-zESHDvABgF61HLPdiUUlDDgNhkgscNXO0vd7anKS58Z3GVqSiMC5HvVs-Cvdf2dFk_-i3JP0S3ihMQlvIyO0WGzXNtngMyafIBu8DmHXzH-MEBHw-H08xS-J6fnHz9B6ygdDfyZx8CL5U_2eTrj
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFH4qRQguiLUEChgJThA1sZ3YPiAELdWULqep1FtwbIdGosnQmREa_gD_ht_Is5NMNSy99Ro7luO3-Ht5G8BLphFUVzmNK2ZtzA1KulRcxLnViTSJdi73icKHR_nomH86yU7W4NeQC-PDKgedGBS1bY3_R75FfWEtwbjg7ybfYt81yntXhxYaHVvsu8V3NNmmb_d2kL6vKN39ON4exX1XgdhkPJ3FzmrNHJo11qhKJZnV3ErHNNWpKhl1QpWZMVwaURqp0UB0acm4dFpZYUtrGK57Da7jxZt4iRInYvlPx1dbl5z3uTkJk1tTHjQRXowoyUJmMV25_0KbgH9h279DNP_w04brb_cO3O5xK3nfMdpdWHPNPbjRdbJc3Iefo8WkrX2uiSNIqzre3kkVMad1cAiFR8ipBNWrm6CVT8bEewympE8EJIjhffw1mc3PcLSPnyd1Q7x7YEHCyq3pMf6M-GgBXM_h0qHJYP3DWXKGOu8BHF8JNR7CetM27hGQrNJZmZeVpYZyWWqEPlkqLK9yJ1JuRATpcPKF6Qug-z4cX4vgiGey6KhVILWKQK2CRvB6-c6kK_9x6ewPnqDLmb50d3jQnn8pek2AJpcWXEkry5zirirEp0xbJ6hW3OWWRbA5sEPR65NpccH9EbxYDqMm8MTSjWvnYY5CYxHxRgQbHfcsd8JQsSMWVBHIFb5a2erqSFOfhmrjvvpTnlA8vjcDC17s6_9n8fjyz3gON0fjw4PiYO9o_wncol5CfAXNZBPWZ-dz9xSh3qx8FuSLwOerFujfF1RrHw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLVKEYgN4k2ggJFgBdEkthPbC4Sgw2hKoWLRSrMzju3QSDQZOhmh4Qf4J76OayeZanh0123sWI7vw-fmvhB6RjWA6jIncUmtjZkBSReS8Ti3OhEm0c7lPlH440E-PWLvZ9lsC_0acmF8WOWgE4Oito3x_8hHxBfW4pRxNir7sIhP48nr-bfYd5DyntahnUbHIvtu9R3Mt8WrvTHQ-jkhk3eHu9O47zAQm4ylbeys1tSBiWONLGWSWc2scFQTncqCEsdlkRnDhOGFERqMRZcWlAmnpeW2sIbCupfQZU6z1MsYn_H1_x1feV0w1ufpJFSMFixoJbgkQaq5yGKycReGlgH_wrl_h2v-4bMNV-HkBrreY1j8pmO6m2jL1bfQla6r5eo2-jldzZvK5504DHSr4t1xKrE5roJzKDwCrsWgat0cLH58iL33YIH7pEAMeN7HYuN2eQKjfSw9rmrsKbLCYeXG9Hi_xT5yANZzsHRoOFj9cBafgP67g44uhBp30Xbd1O4-wlmpsyIvSksMYaLQAIOylFtW5o6nzPAIpcPJK9MXQ_c9Ob6q4JSnQnXUUkAtFailSIRerN-Zd6VAzp391hN0PdOX8Q4PmtMvqtcKYH5pzqSwosgJ7KoErEq1dZxoyVxuaYR2BnZQvW5ZqDNJiNDT9TBoBU8sXbtmGeZIMBwBe0ToXsc9651QUPKAC2WExAZfbWx1c6SujkPlcV8JKk8IHN_LgQXP9vX_s3hw_mc8QVdBlNWHvYP9h-ga8QLii2kmO2i7PV26R4D62uJxEC-MPl-0PP8G0UtvVQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hypoimmune+anti-CD19+chimeric+antigen+receptor+T+cells+provide+lasting+tumor+control+in+fully+immunocompetent+allogeneic+humanized+mice&rft.jtitle=Nature+communications&rft.au=Hu%2C+Xiaomeng&rft.au=Manner%2C+Karl&rft.au=DeJesus%2C+Rowena&rft.au=White%2C+Kathy&rft.date=2023-04-10&rft.issn=2041-1723&rft.eissn=2041-1723&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1038%2Fs41467-023-37785-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41467_023_37785_2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon